DCF Tool

GMED

Globus Medical Inc – Surgical and Medical Instrument Manufacturing
globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
Analysis Results
Intrinsic Value $53.45
Latest Price $50.27
Relative Value 6% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 14.5%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 9.3%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 14.5%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 283 259
2024 324 271
2025 371 284
2026 425 297
2027 486 311
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 6750 million. This corresponds to a present value of 3950 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 1420 million. Adding in the terminal value gives a total present value of 5370 million.

There are presently 100.0 million outstanding shares, so the intrinsic value per share is 53.45.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 983,344,000
Current Cash 446,058,000
Current Liabilities 159,204,000
Current Debt 0
Non-Cash Working Capital (NCWC) 378,082,000
Change in NCWC 97,177,000
EBIT 236,251,000
Tax Provision 52,850,000
Depreciation and Amortization 68,252,000
Capital Expenditure -74,047,000
Unlevered Free Cash Flow 276,254,855
Current Assets 864,516,000
Current Cash 443,447,000
Current Liabilities 140,164,000
Current Debt 0
Non-Cash Working Capital (NCWC) 280,905,000
Change in NCWC 6,673,000
EBIT 194,858,000
Tax Provision 31,216,000
Depreciation and Amortization 69,867,000
Capital Expenditure -56,898,000
Unlevered Free Cash Flow 180,783,529
Current Assets 821,765,000
Current Cash 426,741,000
Current Liabilities 120,792,000
Current Debt 0
Non-Cash Working Capital (NCWC) 274,232,000
Change in NCWC 9,654,000
EBIT 115,472,000
Tax Provision 23,614,000
Depreciation and Amortization 62,874,000
Capital Expenditure -63,658,000
Unlevered Free Cash Flow 102,683,719
Current Assets 687,468,000
Current Cash 311,487,000
Current Liabilities 111,403,000
Current Debt 0
Non-Cash Working Capital (NCWC) 264,578,000
Change in NCWC 69,699,000
EBIT 176,754,000
Tax Provision 34,736,000
Depreciation and Amortization 52,734,000
Capital Expenditure -70,750,000
Unlevered Free Cash Flow 196,113,460
Current Assets 630,681,000
Current Cash 339,684,000
Current Liabilities 96,118,000
Current Debt 0
Non-Cash Working Capital (NCWC) 194,879,000
Change in NCWC 41,317,000
EBIT 176,884,000
Tax Provision 32,131,000
Depreciation and Amortization 41,630,000
Capital Expenditure -59,697,000
Unlevered Free Cash Flow 169,999,805
Current Assets 620,342,000
Current Cash 373,707,000
Current Liabilities 93,073,000
Current Debt 0
Non-Cash Working Capital (NCWC) 153,562,000
Change in NCWC 10,000,000
EBIT 163,451,000
Tax Provision 62,580,000
Depreciation and Amortization 42,067,000
Capital Expenditure -51,303,000
Unlevered Free Cash Flow 104,020,308
Current Assets 513,766,000
Current Cash 290,312,000
Current Liabilities 79,892,000
Current Debt 0
Non-Cash Working Capital (NCWC) 143,562,000
Change in NCWC -37,517,000
EBIT 155,967,000
Tax Provision 52,938,000
Depreciation and Amortization 38,771,000
Capital Expenditure -40,909,000
Unlevered Free Cash Flow 63,815,601
Current Assets 544,799,000
Current Cash 281,029,000
Current Liabilities 82,691,000
Current Debt 0
Non-Cash Working Capital (NCWC) 181,079,000
Change in NCWC 29,170,000
EBIT 172,222,000
Tax Provision 60,021,000
Depreciation and Amortization 24,084,000
Capital Expenditure -50,760,000
Unlevered Free Cash Flow 114,897,495
Current Assets 470,025,000
Current Cash 228,704,000
Current Liabilities 89,412,000
Current Debt 0
Non-Cash Working Capital (NCWC) 151,909,000
Change in NCWC 41,967,000
EBIT 138,362,000
Tax Provision 46,157,000
Depreciation and Amortization 21,754,000
Capital Expenditure -24,754,000
Unlevered Free Cash Flow 131,265,218
Current Assets 416,808,000
Current Cash 238,924,000
Current Liabilities 67,942,000
Current Debt 0
Non-Cash Working Capital (NCWC) 109,942,000
Change in NCWC 1,740,000
EBIT 101,673,000
Tax Provision 33,389,000
Depreciation and Amortization 19,397,000
Capital Expenditure -23,680,000
Unlevered Free Cash Flow 65,848,367

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.